Zyprexa Articles
Strong results for B-MS/Otsuka's Abilify
20 March 2006
Eli Lilly charity leaflet banned by UK regulator
20 February 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Pfzizer's Geodon fares well vs placebo and Zyprexa
15 August 2005
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Lilly agrees $690M Zyprexa settlement
20 June 2005
Eli Lilly's olanzapine: better compliance
6 June 2005
Positive results for AstraZeneca's Seroquel
30 May 2005
Stock Commentary - New York
25 April 2005
Corcept's Corlux shows good weight loss result
25 April 2005
Eli Lilly reports 84% income rise in 1st qtr
25 April 2005
US court upholds Lilly's Zyprexa patent
25 April 2005
Australia backtracks on 12.5% generic price cut
14 February 2005
New product launches in 2004
31 January 2005
Benefits of long-term Zyprexa therapy
20 December 2004
Barr confirms challenge to Zyprexa patent
13 December 2004
Stock Commentary - New York
1 November 2004
Eli Lilly's income up 6% for 3rd-qtr 2004
1 November 2004
Stock Commentary - New York
25 October 2004
Florida curbs off-label use of five Rx drugs
16 August 2004
Stock Commentary - New York
24 May 2004
AstraZeneca's 1st-qtr sales pass $5 billion
3 May 2004
Lilly sees sales climb 17% for 1st-qtr 2004
26 April 2004
Class action filed over Zyprexa side effects
26 April 2004
Stock Commentary - New York
5 April 2004
FDA appro for Lilly's injectable Zyprexa
5 April 2004
FDA appro for Lilly's injectable Zyprexa
5 April 2004
Injectable Zyprexa launched in UK by Lilly
9 February 2004
Strong 2003 sales for Lilly but profits flat
9 February 2004
UPDATE: Lilly's Zyprexa gets OK from FDA for new use
26 January 2004
Lilly's Zyprexa gets OK from FDA for new use
19 January 2004
Indian firms urge govt over life-saving drugs
5 January 2004
Lilly drug cleared for depressive bipolar disease
5 January 2004
Launches hit Lilly's profits, sales strong
27 October 2003
New NICE guidances for England and Wales
6 October 2003
Positive results with AstraZeneca Seroquel
29 September 2003
Lilly receives product labeling letter from FDA
29 September 2003
US FDA seizes "potentially dangerous" drugs from repackager
22 September 2003
Lilly gains positive opinion for new Zyprexa use
4 August 2003
Zyprexa lifts Eli Lilly above estimates
4 August 2003
Farmaindustria sues over antipsychotic visas
28 July 2003
Lilly gains FDA OK for new Zyprexa use
21 July 2003
Swiss OK for new use of Novartis' Leponex
21 July 2003
Lilly plans major Spanish investment
2 June 2003
Crestor advisory panel raises fears of delay
26 May 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
Underlying growth beats forecasts at Lilly
28 April 2003
Stock Commentary - New York
21 April 2003
Lilly's Zyprexa faces new patent challenge
17 March 2003
Lilly sued over alleged Zyprexa side effects
10 March 2003
2003 will fall below forecast, says Eli Lilly
10 February 2003
Shire hit by Adderall XR patent challenge
13 January 2003
Zyprexa - placebo-like levels of EPS
19 August 2002
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
Correction: Zyprexa in bipolar disorder
15 July 2002
Alkermes posts increased loss of $61M for 2002
8 July 2002
Risperdal Consta not approvable, says FDA
8 July 2002
Injectable form of Geodon cleared in USA
1 July 2002
Lilly combination works in bipolar depression
1 July 2002
Correction: Eli Lilly's Zyprexa
24 June 2002
Eli Lilly's Zybprexa awarded new European license
17 June 2002
Patent ruling boosts Pakistani pharma
18 February 2002
Eli Lilly earnings take a tumble
28 January 2002
Lilly and FDA talking about plant problems
7 January 2002
Lilly and FDA talking about plant problems
19 December 2001
Seroquel compliance tops competitors
12 November 2001
Eli Lilly adding 5,000 more sales reps
26 October 2001
Net oncome down 7% at Lilly
18 October 2001
Lilly reports successful Zyprexa trials
15 October 2001
J&J files for depot form of Risperdal
6 September 2001
Cipla signs deal with IVAX affiliate
5 September 2001
New drugs lift Lilly's 2nd qtr sales 16%
23 July 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
